Dickmeyer Boyce Financial Management Inc. Makes New $386,000 Investment in Novo Nordisk A/S $NVO

Dickmeyer Boyce Financial Management Inc. acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the first quarter, according to its most recent disclosure with the SEC. The fund acquired 10,505 shares of the company’s stock, valued at approximately $386,000.

A number of other hedge funds also recently made changes to their positions in NVO. Godfrey Financial Associates Inc. purchased a new stake in Novo Nordisk A/S in the 4th quarter worth approximately $25,000. Scarborough Advisors LLC bought a new position in shares of Novo Nordisk A/S in the first quarter worth approximately $26,000. WealthCollab LLC boosted its position in shares of Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after purchasing an additional 260 shares during the period. American National Bank & Trust purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter worth $28,000. Finally, Maseco LLP bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at $29,000. 11.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday. Finally, Wolfe Research assumed coverage on Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating on the stock. Five investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $48.18 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The company has a market cap of $215.12 billion, a P/E ratio of 11.31, a P/E/G ratio of 4.39 and a beta of 0.77. The firm’s fifty day moving average is $46.28 and its two-hundred day moving average is $45.72. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $71.79.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The business had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. As a group, analysts anticipate that Novo Nordisk A/S will post 3.39 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.